AMRN
vs
S&P 500
AMRN
S&P 500
Over the past 12 months, AMRN has significantly outperformed S&P 500, delivering a return of +55% compared to the S&P 500's +13% growth.
Stocks Performance
AMRN vs S&P 500
Performance Gap
AMRN vs S&P 500
Performance By Year
AMRN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Amarin Corporation PLC
Glance View
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. The firm is focused on the commercialization and development of therapeutics for cardiovascular disease management. The firm operates through the development and commercialization of Vascepa segment. Its lead product, Vascepa (icosapent ethyl) capsule for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The firm sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.